In a nutshell This study evaluated the effectiveness and safety of osimertinib (Tagrisso) as first-line therapy for older patients above 75 years with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). The data showed that osimertinib as first-line therapy is effective in these patients. However, osimertinib was...
Read More
In a nutshell This study investigated the effectiveness and safety of camrelizumab (SHR1210) in combination with XELOX (capecitabine and oxaliplatin) chemotherapy plus bevacizumab (Avastin) or regorafenib (Stivarga) as first-line therapy in patients with metastatic colorectal cancer (mCRC). The data showed that the combination was effective for these...
Read More
In a nutshell This study investigated the effectiveness and safety of combining proton radiotherapy (PRT) plus carbon-ion radiotherapy (CIRT) with chemotherapy (CT) given at the same time in patients with limited-stage (LS) small cell lung cancer (SCLC). The data showed that PRT plus CIRT with CT given at the same time was effective with manageable side...
Read More
In a nutshell This study evaluated the effectiveness and safety of radiotherapy (RT) for the treatment of patients with indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that RT was highly effective with manageable side effects in these patients. Some background Non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells...
Read More
In a nutshell This study aimed to investigate the combination of clofarabine (Clolar)-fludarabine (Fludara)-busulfan (Busulfex) as a conditioning regime in hematopoietic stem cell transplant (HSCT) for children with acute leukemia. This study concluded that this combination is safe and effective in these patients. Some...
Read More
In a nutshell This study evaluated the effectiveness and safety of docetaxel (Taxotere) given every 2 weeks plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC). The data showed that docetaxel given every 2 weeks plus ADT was safe and effective in these patients. Some background MCNPC...
Read More
In a nutshell These guidelines aimed to update treatment options for patients with Philadelphia chromosome-positive (Ph+) and negative (Ph-) acute lymphoblastic leukemia (ALL). Some background Acute lymphoblastic leukemia (ALL) represents 75% to 80% of acute leukemia among children and so is the most common form of childhood leukemia. It represents...
Read More
In a nutshell This study compared the effectiveness and safety of tibial nerve stimulation (TNS) versus antimuscarinic agents for the treatment of patients with overactive bladder (OAB). The study found that TNS was safer and as effective as antimuscarinic agents for the treatment of OAB. Some background Overactive bladder (OAB) occurs when the...
Read More
In a nutshell This study investigated whether a combination pill given in fixed doses with or without aspirin can reduce the risk of cardiovascular disease events in patients without a previous history of cardiovascular disease. The data showed that a fixed-dose combination treatment strategy with aspirin significantly reduced the risks of...
Read More
In a nutshell This study compared the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC). The data showed that alectinib (Alecensa) and lorlatinib (Lorbrena) were the most effective and safest first-line treatment options for these patients. Some background...
Read More
In a nutshell This study compared the effectiveness of adding immunotherapy (IT) to chemotherapy (CT) for the treatment of patients with metastatic triple-negative breast cancer (TNBC). The data showed that the addition of IT to CT significantly improved survival without cancer worsening. However, IT plus CT combination did not...
Read More
In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities) can be found in...
Read More
